Injection products include chemicals, biological products, Chinese proprietary medicines, injection has always been the key product of pharmaceutical companies, and its market is also expanding
.
For example, the market for chemical injections has grown from 408.
5 billion yuan in 2013 to 615.
2 billion yuan
in 2018.
At the same time, although the sales scale of the injection market declined due to the epidemic in 2020, it warmed up again in 2021, and the sales scale of that year exceeded 600 billion yuan, a year-on-year increase of 10%.
At present, under the attraction of the huge market, domestic pharmaceutical companies are accelerating the development of
injection products.
It is worth mentioning that there have been good news
from many pharmaceutical companies in this field recently.
For example, on November 30, Keyin Technology announced that the clinical trial application of human interferon α2b spray for the treatment of herpangina in children caused by viral infection was approved
by the State Food and Drug Administration.
Human interferon α2b spray is a new drug delivery preparation developed on the basis of the company's listed variety human interferon α2b injection, which is convenient for administration and more suitable for oral mucosal topical medicine; Packaged in bactericidal spray bottles, it does not contain preservatives, making the product safer
.
On the same day, Kain Technology also announced that the clinical trial application for the indication of shingles of interferon α-2 injection was approved
by the State Food and Drug Administration.
Peiji interferon α-2 injection (trade name: Derivative) ® is an antiviral drug with independent intellectual property rights of the company, which belongs to therapeutic biological products and has a new drug certificate
.
The product is applied for the indication of
increasing herpes zoster in this clinical trial.
On November 29, Wanbond issued an announcement that Wanbond Pharmaceutical Group Co.
, Ltd.
, a wholly-owned subsidiary of the company, received the "Drug Registration Certificate" of the State Medical Products Administration for bromohexine hydrochloride injection, certificate number: 2022S01140
.
It is reported that bromohexine hydrochloride injection is a variety of the 2021 edition of the national medical insurance catalog, which has a strong effect of dissolving mucus sputum, which can make the polysaccharide cellulose in sputum lyse and dilute sputum
.
Inhibit the synthesis of glycoproteins by goblet cells and mucus glands, reduce sialic acid in sputum, reduce sputum viscosity, and facilitate excretion
.
It is mainly used for patients with chronic bronchitis and other respiratory diseases such as asthma, bronchiectasis, silicosis, etc.
who have sticky sputum and are not easy to cough up in the case of difficult oral administration
.
It is worth mentioning that Buchang Pharmaceutical also issued an announcement that Tonghua Guhong Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the company, has recently received the "Drug Registration Certificate"
for ambroxol hydrochloride injection approved and issued by the State Medical Products Administration.
In addition, Zhongyuan Xiehe issued an announcement that Wuhan Optics Valley Zhongyuan Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the company, has obtained the "Notice of Acceptance" for the clinical trial application of VUM02 injection issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration on November 22, with the acceptance number CXSL2200586
.
VUM02 injection (human umbilical cord-source mesenchymal stem cell injection) is a cryopreserved stem cell preparation independently developed by Sinogenous Concord, which is a human umbilical cord-derived mesenchymal stem cell (UC-MSC) suspension prepared by isolation, screening and expansion of healthy fetal umbilical cord tissue in vitro, and is clinically intended for the treatment of patients
with decompensated liver cirrhosis.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
